Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

Dow Jones

Mar 27, 2025

1755 ET - Alcon's purchase of a majority of Aurion Biotech, which is developing cell therapies for eye diseases, follows a contentious relationship between the companies. Alcon invested in Aurion in 2022 and sued it last October, and Aurion countersued in November. Alcon opposed Aurion's planned initial public offering. Aurion said it had "rejected multiple inadequate bids" from Alcon. Aurion filed for the IPO confidentially in October and disclosed its plans in January. In the risk factors section of its filing, the company said "We are currently engaged in litigation against our largest stockholder, Alcon." Alcon joined a $120 million Series C financing in 2022 led by Deerfield Management. As of January, other top shareholders included Petrichor and KKR-backed Falcon Vision. (josh.beckerman@wsj.com)

(END) Dow Jones Newswires

March 26, 2025 17:55 ET (21:55 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522351585"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522351585\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522351585?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522351585","market":"sg","top_or_hot":-1,"title":"Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1755 ET - Alcon's purchase of a majority of Aurion Biotech, which is developing cell therapies for eye diseases, follows a contentious relationship between the companies. Alcon invested in Aurion in 2022 and sued it last October, and Aurion countersued in November. Alcon opposed Aurion's planned initial public offering. Aurion said it had \"rejected multiple inadequate bids\" from Alcon. Aurion filed for the IPO confidentially in October and disclosed its plans in January. In the risk factors section of its filing, the company said \"We are currently engaged in litigation against our largest stockholder, Alcon.\" Alcon joined a $120 million Series C financing in 2022 led by Deerfield Management. As of January, other top shareholders included Petrichor and KKR-backed Falcon Vision. (josh.beckerman@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 26, 2025 17:55 ET (21:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-27 05:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1755 ET - Alcon's purchase of a majority of Aurion Biotech, which is developing cell therapies for eye diseases, follows a contentious relationship between the companies. Alcon invested in Aurion in 2022 and sued it last October, and Aurion countersued in November. Alcon opposed Aurion's planned initial public offering. Aurion said it had \"rejected multiple inadequate bids\" from Alcon. Aurion filed for the IPO confidentially in October and disclosed its plans in January. In the risk factors section of its filing, the company said \"We are currently engaged in litigation against our largest stockholder, Alcon.\" Alcon joined a $120 million Series C financing in 2022 led by Deerfield Management. As of January, other top shareholders included Petrichor and KKR-backed Falcon Vision. (josh.beckerman@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 26, 2025 17:55 ET (21:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1668664300.SGD","symbol_name":"Blackrock World Financials A2 SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2522351585","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522351585","pubTimestamp":1743026100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1755 ET - Alcon's purchase of a majority of Aurion Biotech, which is developing cell therapies for eye diseases, follows a contentious relationship between the companies. Alcon invested in Aurion in 2022 and sued it last October, and Aurion countersued in November. Alcon opposed Aurion's planned initial public offering. Aurion said it had \"rejected multiple inadequate bids\" from Alcon. Aurion filed for the IPO confidentially in October and disclosed its plans in January. In the risk factors section of its filing, the company said \"We are currently engaged in litigation against our largest stockholder, Alcon.\" Alcon joined a $120 million Series C financing in 2022 led by Deerfield Management. As of January, other top shareholders included Petrichor and KKR-backed Falcon Vision. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1935043023.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (USD) INC A","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1935042215.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC A","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4135":"资产管理与托管银行","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","ALC":"Alcon Inc","LU1935043536.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME \"AA\" (SGDHDG) INC A","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","KKR":"KKR & Co L.P.","LU1935042488.USD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (USD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","LU0106831901.USD":"贝莱德世界金融基金A2","BK4534":"瑞士信贷持仓"},"translate_title":"爱尔康在2022年投资、2024年诉讼之后收购Aurion——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KKR":0.9,"ALC":0.9},"content_text":"1755 ET - Alcon's purchase of a majority of Aurion Biotech, which is developing cell therapies for eye diseases, follows a contentious relationship between the companies. Alcon invested in Aurion in 2022 and sued it last October, and Aurion countersued in November. Alcon opposed Aurion's planned initial public offering. Aurion said it had \"rejected multiple inadequate bids\" from Alcon. Aurion filed for the IPO confidentially in October and disclosed its plans in January. In the risk factors section of its filing, the company said \"We are currently engaged in litigation against our largest stockholder, Alcon.\" Alcon joined a $120 million Series C financing in 2022 led by Deerfield Management. As of January, other top shareholders included Petrichor and KKR-backed Falcon Vision. (josh.beckerman@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 17:55 ET (21:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}